Article
Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents
25 Jun 2020
Abstract excerpt
Inhibitors of B-cell receptor signalling, ibrutinib and idelalisib, and BCL-2 antagonist, venetoclax, have become the mainstay of treatment for chronic lymphocytic leukaemia (CLL). Despite significant efficacy in most CLL patients, some patients develop resistance to these agents and progress on these drugs. We provide state-of-the-art overview of the acquired resistance to novel agents. In 80% of patients with...
Topics
Join the communities discussing this publication.